Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Headquartered in Dallas, Texas, the company aims to address rare neurodevelopmental disorders that lack approved disease-modifying treatments. Its lead clinical program, TSHA-102, is currently in development for the treatment of Rett syndrome. The company was founded in partnership with the University of Texas Southwestern Medical Center to translate early-stage gene therapy research into commercial treatments. Taysha leverages a clinically and commercially proven AAV9 capsid to deliver its therapies intrathecally directly to the central nervous system. While the company previously maintained a broader pipeline of preclinical assets, it has streamlined its operations to focus capital and resources primarily on its most advanced clinical programs.
